Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.
Seventy-nine patients with cutaneous (62) or mucosal (17) infection with Leishmania (Viannia) braziliensis in Três Braços, Bahia, Brazil, were followed for at least 4 years after initiating treatment with antimony. Cutaneous relapses occurred in 6/62 (10%), mucosal relapse after cutaneous infection in 2/62 (3%), and mucosal relapse after mucosal disease in 2/17 (17%). It is concluded that relapse (cutaneous and mucosal) is rare after adequate antimony therapy and that no definite prediction of relapse (clinical, serological or by skin reaction) is possible.
Netto
E M
EM
Núcleo de Medicina Tropical e Nutrição, Universidade de Braília, Brazil.
Marsden
P D
PD
Llanos-Cuentas
E A
EA
Costa
J M
JM
Cuba
C C
CC
Barreto
A C
AC
Badaró
R
R
Johnson
W D
WD
Jones
T C
TC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007892:Leishmania braziliensis; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012008:Recurrence; D012883:Skin Ulcer / Q000188:drug therapy; D013997:Time Factors
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony